 |
Article dans une revue
Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction
Abstract : Ivabradine is an original drug that has been approved in two indications (systolic heart failure and angina). The aim of this short review is to draw the attention of clinician prescribers to the evidence base of ivabradine. Three large randomized trials testing ivabradine versus placebo have been performed. The BEAUTIFUL and SIGNIFY trials were in fact negative in the treatment of angina while the SHIFT trial found a marginal benefit of ivabradine over placebo in the treatment of heart failure. These important results are put into perspective in order to improve the assessment of risk-cost/benefit balances when ivabradine is considered. Ideally, a further clinical trial investigating the use of ivabradine in heart failure should be carried out with optimal treatment of the patient population in order to identify the subgroup of patients who respond to ivabradine.
https://hal-u-picardie.archives-ouvertes.fr/hal-03583873
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mardi 22 février 2022 - 10:01:31
Dernière modification le : mercredi 23 février 2022 - 03:14:09
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mardi 22 février 2022 - 10:01:31
Dernière modification le : mercredi 23 février 2022 - 03:14:09